Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
9.8.2023 09:00:00 EEST | Business Wire | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI), in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
The phase II clinical trial (NCT05268016)* was conducted to evaluate the efficacy, safety and tolerability of ME3183 after administered once or twice daily for 16 weeks in patients with moderate-to-severe plaque psoriasis. One-hundred and thirty-two patients were enrolled in the United States and Canada. The primary endpoint was defined as the proportion of subjects achieving 75% improvement (“PASI-75”) in Psoriasis Area Severity Index (PASI) Score at Week 16 from baseline. As a result, significantly greater proportion of PASI-75 achievement were observed in ME3183 treatment groups compared to the placebo group, which met the primary endpoint. In addition, early PASI improvement after administration was observed in ME3183 groups. ME3183 was shown to be safe and well tolerated. Details of the study will be presented at an upcoming medical meeting.
ME3183 is an orally-available and selective PDE4 inhibitor discovered by Meiji Seika Pharma. In non-clinical studies, it showed greater anti-inflammatory effect and approximately 30-fold greater inhibitory effect on TNF-α production than the existing orally-available PDE4 inhibitor for psoriasis. At the same time, the distribution of ME3183 in the brain was sufficiently low.
Meiji strives to provide efficacious and safe treatment for unmet medical needs, such as psoriasis and other autoimmune diseases.
*: Meiji Pharma USA Inc. (Teaneck, NJ, President: Yasushi Miyazawa), a wholly owned subsidiary of Meiji, is in charge of the Phase II clinical trial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808681726/en/
Contact information
Meiji Pharma USA Inc.
Yasushi Miyazawa
President
Telephone: 201-777-7133
E-mail: mpu.contact@meiji-us.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils Ling-3.0-Flash Delivering Top-Tier Performance at a Fraction of the Parameter Scale27.7.2026 09:00:00 EEST | Press release
Ant Group today announced the release of Ling-3.0-Flash, a next-generation native hybrid-reasoning foundational model engineered specifically for production-grade AI agent workflows. Designed to deliver rapid response capabilities, it serves as a high-speed execution node that offers a superior balance of intelligence density and cost-efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260726584441/en/ Ling-3.0-Flash delivers strong performance across multiple core benchmarks. Featuring 124B total parameters with only 5.1B active parameters per token, Ling-3.0-Flash achieves remarkable performance despite its streamlined footprint. It matches or surpasses industry-leading models with two to three times its parameter scale across core benchmarks, including foundational reasoning, instruction following, and long-context processing. Architectural Innovation for Efficiency Ling-3.0-Flash moves away from the traditional ap
SES Statement On FCC Upper C-band Auction Decision27.7.2026 08:30:00 EEST | Press release
SES, a leading space solutions company, issued the following statement following the U.S. Federal Communications Commission approval of the Upper C-band Report & Order that makes 160 megahertz of the Upper C-band available in the contiguous United States for flexible-use, next-generation terrestrial wireless services via a system of competitive bidding. The required auction of the Upper C-band will be completed no later than July 2027, with spectrum clearing deadlines in 2030 and 2031. Gross incentive payments of approximately $5.6 billion to SES are contingent on spectrum clearing within the transition deadlines. The Order also confirms reimbursement of reasonable and necessary Upper C-band transition costs as approved by the clearinghouse. SES CEO Adel Al-Saleh Commented: “We commend Chairman Carr and the FCC staff for their diligence, speed, and hard work. We remain fully committed to working cooperatively with the FCC and all stakeholders as the process progresses. We are pleased t
LTM and Cognition Partner to Reduce Cyber Risk in Financial Services with Devin27.7.2026 08:00:00 EEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic partnership with Cognition, the AI lab behind the software engineering agent Devin. As a part of this partnership, LTM has onboarded Devin, Cognition’s Autonomous AI Engineer as part of BlueVerseTM RightLogic. LTM BlueVerse RightLogic, is a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. Together, the companies will prioritize financial services sector, where Devin is most proven and where LTM brings deep institutional expertise. As AI adoption accelerates, many financial institutions are facing a widening gap between innovation and cyber risk visibility. BlueVerse RightLogic closes this gap by autonomously identifying, prioritizing and remediating vulnerabilities across banking infrastructure, applications, AI systems, software supply chains and governance—including exploits
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 14:00:00 EEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performance, reliability and trusted supply chains. Its drones support national security and public-safety operations, sear
Enhertu ® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 14:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DESTI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom